Zimmer Biomet stock slips after Winterthur job-cut plan and leadership changes
Published on 09/11/2026 at 14:42 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Zimmer Biomet Holdings Inc. stock (ISIN US98956P1021) closed at USD 92.44 on the New York Stock Exchange on September 10, 2026, down 2.29% from a prior close of USD 94.61 according to exchange data cited by Yahoo Finance, leaving the shares well above their recent 52-week low of USD 79.12 but still below highs above USD 100 seen in August 2026.
Restructuring drive includes up to 580 job cuts
As MassDevice reported on September 10, 2026, Zimmer Biomet plans to restructure operations in Switzerland, with up to 580 jobs to be cut at its Winterthur site, representing about 3.4% of its roughly 17,000 positions worldwide.
According to Swissinfo on September 11, 2026, the city government of Winterthur expressed strong concern over the proposed job reductions and noted that Zimmer Biomet had indicated the cuts were not yet final, with a consultation process still under way.
Stock reaction and valuation context
Zimmer Biomet shares have retreated from levels above USD 100 in August 2026 to USD 92.44 by September 10, 2026, with technical commentary from Adalytica highlighting that the stock is trading below both its 50-day and 200-day moving averages and that the recent pullback has pushed the relative strength index near 30, a zone often associated with oversold conditions.
Shares of Zimmer Biomet opened around USD 92.30 on September 11, 2026, giving the company a market capitalization of roughly USD 17.61 billion and a price-to-earnings ratio of 22.46 based on data compiled by MarketBeat on September 11, 2026, which also cited a consensus analyst target price of USD 104.42.
Q1 2026 results show revenue growth
Reviewing fundamentals, Zimmer Biomet reported net sales of USD 2.087 billion for the first quarter of 2026, an increase of 9.3% on a reported basis versus the prior year period and 2.9% growth excluding foreign exchange and the impact of the Paragon 28 acquisition, according to the company's Q1 2026 earnings call transcript published by Fortune on April 28, 2026.
In the same Q1 2026 period, Zimmer Biomet highlighted that consolidated pricing pressure amounted to around 40 basis points negative, while adjusted net interest and non-operating expenses reached USD 71 million, higher than the prior year due to increased debt associated with the Paragon 28 deal, as detailed in the earnings call transcript from Fortune.
Leadership changes and dividend signal ongoing strategy
Zimmer Biomet has also been active on the leadership and governance front, with Yahoo Finance reporting on September 10, 2026 that the company reiterated its 2026 outlook amid leadership changes, aiming to streamline operations and stay on track to meet its financial targets.
The same Yahoo Finance overview noted that Zimmer Biomet declared a cash dividend of USD 0.24 per share with an ex-dividend date of September 30, 2026, corresponding to a forward dividend of USD 0.96 and a yield of about 1.01%, giving income-focused investors a modest yield while restructuring and growth initiatives continue.
Analyst views and price targets provide benchmarks
Analyst sentiment toward Zimmer Biomet remains mixed but generally constructive, with MarketBeat citing on September 11, 2026 that the stock carries a consensus rating of Hold and an average analyst price target of USD 104.42, implying roughly a 13% upside from the September 10, 2026 close of USD 92.44.
In a separate datapoint, Yahoo Finance highlighted that Canaccord Genuity maintained its Hold rating on Zimmer Biomet while raising its price target from USD 83 to USD 100 on August 10, 2026, suggesting that the broker sees improved prospects compared with earlier expectations but still advises caution.
Risks, opportunities and investor perspective
The planned reduction of up to 580 roles in Winterthur underscores Zimmer Biomet's push to align its cost base with revenue growth and margin objectives, but it also introduces execution risk and potential reputational pressure as local authorities and employees respond to the proposed cuts, as noted by both MassDevice and Swissinfo.
At the same time, the first quarter of 2026 showed that Zimmer Biomet can deliver mid-single-digit underlying growth, with net sales up 9.3% year on year and 2.9% on a basis excluding foreign exchange and M&A, while absorbing pricing pressure and higher interest costs, according to the Q1 2026 earnings call coverage from Fortune, which suggests that investors are likely to focus on whether restructuring steps help sustain that growth trajectory and improve margins in the second half of 2026.
Zimmer Biomet stock level and trading data
Zimmer Biomet stock ended regular trading on the New York Stock Exchange at USD 92.44 on September 10, 2026 at 4:00 p.m. Eastern Time, with after-hours trading indicated at the same level at 5:05 p.m. Eastern Time according to Yahoo Finance; at this price, the shares trade below the average analyst target of USD 104.42 and remain above the recent 52-week low of USD 79.12 referenced in recent market summaries.
Zimmer Biomet stock - key data
- Company: Zimmer Biomet Holdings Inc.
- ISIN: US98956P1021
- Ticker: ZBH
- Trading venue: New York Stock Exchange
- Price (as of September 10, 2026, 16:00): 92.44 USD
- Market capitalization: 17.61 billion USD (as of September 11, 2026)
- Sector / Industry: Health Care / Medical Devices
- Index membership: S&P 500
- Next earnings date: September 30, 2026
